Alk-Abello AS Class B ALK B
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- DKK 197.50
- Day Range
- DKK 196.30–204.00
- 52-Week Range
- DKK 191.80–271.40
- Bid/Ask
- DKK 202.20 / DKK 202.80
- Shares Outstanding
- 221.88M
- Market Cap
- DKK 44.73B
- Volume/Avg
- 219,254 / 183,899
Key Statistics
- Price/Earnings (Normalized)
- 32.00
- Price/Sales
- 6.43
- Dividend Yield (Trailing)
- 0.79%
- Dividend Yield (Forward)
- 0.79%
- Dividend Payment Schedule
- Mar
- Total Yield
- 0.79%
Company Profile
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 2,759
- Website
- https://www.alk.net
Valuation
|
Metric
|
ALK B
|
|---|---|
Price/Earnings (Normalized) | 32.00 |
Price/Book Value | 6.31 |
Price/Sales | 6.43 |
Price/Cash Flow | 20.31 |
Price/Earnings
ALK B
Financial Strength
|
Metric
|
ALK B
|
|---|---|
Quick Ratio | 2.09 |
Current Ratio | 3.46 |
Interest Coverage | — |
Quick Ratio
ALK B
Profitability
|
Metric
|
ALK B
|
|---|---|
Return on Assets (Normalized) | 15.50% |
Return on Equity (Normalized) | 21.73% |
Return on Invested Capital (Normalized) | 19.86% |
Return on Assets
ALK B
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|??R<%QC | LOCK|V<@N | $128B | |||
| Moderna Inc
MRNA
| LOCK|!Hj$$& | LOCK|$yL | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%>#K>^F | LOCK|<f>ml | $76B | |||
| argenx SE ADR
ARGX
| LOCK|>sBn?B | LOCK|v<< | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|!H^b%> | LOCK|x< | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|#mr!p? | LOCK|ydzx | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<$CLztV> | LOCK|j^Csp | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|@<#hRHN | LOCK|W@V | $24B | |||
| Incyte Corp
INCY
| LOCK|QVn&Mt$ | LOCK|nw | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|t?L?F$ | LOCK|@W& | $15B |
United States